TWD 22.25
(0.23%)
Year | Operating Income | Operating Income Growth |
---|---|---|
2023 | 211.01 Million TWD | 0.36% |
2022 | 210.26 Million TWD | -2.86% |
2021 | 216.44 Million TWD | 20.64% |
2020 | 179.41 Million TWD | 28.16% |
2019 | 139.99 Million TWD | 1.76% |
2018 | 137.56 Million TWD | -13.47% |
2017 | 158.99 Million TWD | 24.72% |
2016 | 127.47 Million TWD | 12.75% |
2015 | 113.05 Million TWD | 48.47% |
2014 | 76.14 Million TWD | 0.78% |
2013 | 75.55 Million TWD | 18.66% |
2012 | 63.67 Million TWD | 168.96% |
2011 | 23.67 Million TWD | -25.87% |
2010 | 31.93 Million TWD | 149.09% |
2009 | 12.82 Million TWD | 0.0% |
Year | Operating Income | Operating Income Growth |
---|---|---|
2024 Q2 | 50.51 Million TWD | -30.7% |
2024 Q1 | 72.89 Million TWD | 90.48% |
2023 Q2 | 54.99 Million TWD | -18.98% |
2023 Q1 | 67.88 Million TWD | 131.13% |
2023 Q4 | 38.27 Million TWD | -23.25% |
2023 Q3 | 49.86 Million TWD | -9.33% |
2023 FY | 211.01 Million TWD | 0.36% |
2022 Q1 | 65.14 Million TWD | 133.45% |
2022 Q3 | 56.02 Million TWD | -6.15% |
2022 FY | 210.26 Million TWD | -2.86% |
2022 Q4 | 29.37 Million TWD | -47.57% |
2022 Q2 | 59.69 Million TWD | -8.36% |
2021 FY | 216.44 Million TWD | 20.64% |
2021 Q1 | 62.41 Million TWD | 128.33% |
2021 Q2 | 55.89 Million TWD | -10.45% |
2021 Q3 | 48.38 Million TWD | -13.43% |
2021 Q4 | 27.9 Million TWD | -42.33% |
2020 FY | 179.41 Million TWD | 28.16% |
2020 Q2 | 34.75 Million TWD | -35.76% |
2020 Q1 | 54.1 Million TWD | 131.08% |
2020 Q3 | 54.14 Million TWD | 55.77% |
2020 Q4 | 27.33 Million TWD | -49.51% |
2019 Q1 | 48.24 Million TWD | 209.58% |
2019 Q3 | 40.72 Million TWD | 14.58% |
2019 Q4 | 23.41 Million TWD | -42.51% |
2019 FY | 139.99 Million TWD | 1.76% |
2019 Q2 | 35.54 Million TWD | -26.33% |
2018 FY | 137.56 Million TWD | -13.47% |
2018 Q2 | 36.47 Million TWD | -11.6% |
2018 Q1 | 41.26 Million TWD | 9.75% |
2018 Q4 | 15.58 Million TWD | -64.78% |
2018 Q3 | 44.24 Million TWD | 21.31% |
2017 Q2 | 38.79 Million TWD | 2.87% |
2017 Q3 | 44.9 Million TWD | 15.76% |
2017 FY | 158.99 Million TWD | 24.72% |
2017 Q1 | 37.7 Million TWD | -9.52% |
2017 Q4 | 37.59 Million TWD | -16.28% |
2016 Q3 | 32.47 Million TWD | 30.2% |
2016 FY | 127.47 Million TWD | 12.75% |
2016 Q4 | 41.67 Million TWD | 28.34% |
2016 Q2 | 24.94 Million TWD | -12.16% |
2016 Q1 | 28.39 Million TWD | -19.09% |
2015 Q2 | 15.97 Million TWD | -60.98% |
2015 Q1 | 40.93 Million TWD | 36.03% |
2015 FY | 113.05 Million TWD | 48.47% |
2015 Q4 | 35.08 Million TWD | 66.57% |
2015 Q3 | 21.06 Million TWD | 31.9% |
2014 Q3 | 9.63 Million TWD | -24.45% |
2014 Q2 | 12.75 Million TWD | -46.07% |
2014 FY | 76.14 Million TWD | 0.78% |
2014 Q1 | 23.65 Million TWD | -24.52% |
2014 Q4 | 30.09 Million TWD | 212.17% |
2013 Q4 | 31.34 Million TWD | 70.77% |
2013 Q2 | 8.3 Million TWD | -52.7% |
2013 Q3 | 18.35 Million TWD | 121.03% |
2013 FY | 75.55 Million TWD | 18.66% |
2013 Q1 | 17.55 Million TWD | -48.27% |
2012 Q4 | 33.93 Million TWD | 408.27% |
2012 Q1 | 19.24 Million TWD | 10.78% |
2012 Q2 | 4.05 Million TWD | -78.91% |
2012 Q3 | 6.67 Million TWD | 64.54% |
2012 FY | 63.67 Million TWD | 168.96% |
2011 FY | 23.67 Million TWD | -25.87% |
2011 Q3 | -1.57 Million TWD | 87.27% |
2011 Q2 | -12.36 Million TWD | -161.08% |
2011 Q1 | 20.23 Million TWD | 999.78% |
2011 Q4 | 17.37 Million TWD | 1203.75% |
2010 Q3 | 5.03 Million TWD | -41.65% |
2010 Q2 | 8.62 Million TWD | -58.02% |
2010 FY | 31.93 Million TWD | 149.09% |
2010 Q1 | 20.53 Million TWD | 0.0% |
2010 Q4 | -2.24 Million TWD | -144.71% |
2009 FY | 12.82 Million TWD | 0.0% |
Name | Operating Income | Operating Income Difference |
---|---|---|
Grape King Bio Ltd | 2.49 Billion TWD | 91.548% |
Standard Chem & Pharm CO., LTD. | 1.25 Billion TWD | 83.247% |
ScinoPharm Taiwan, Ltd. | 314.49 Million TWD | 32.901% |
Lotus Pharmaceutical Co., Ltd. | 4.9 Billion TWD | 95.696% |
LIWANLI Innovation Co., Ltd. | - TWD | -Infinity% |
YungShin Global Holding Corporation | 929.61 Million TWD | 77.3% |
PhytoHealth Corporation | -121.67 Million TWD | 273.426% |
SCI Pharmtech, Inc. | 160.3 Million TWD | -31.64% |
Formosa Laboratories, Inc. | 674.97 Million TWD | 68.737% |
PharmaEssentia Corporation | - TWD | -Infinity% |
Bora Pharmaceuticals Co., LTD. | 5.24 Billion TWD | 95.98% |